Open-label study to evaluate the use of imiquimod 5% cream for reducing postsurgical recurrence or persistence of basal cell carcinoma following excision by curettage.
Phase of Trial: Phase III
Latest Information Update: 15 Jul 2010
At a glance
- Drugs Imiquimod (Primary)
- Indications Basal cell cancer
- Focus Therapeutic Use
- 15 Jul 2010 Additional lead trial center (Medicis Global Service Corporation) identified as reproted by ClinicalTrials.gov.
- 15 Jul 2010 Companies added in association field as reported by ClinicalTrials.gov.
- 14 Jul 2010 Actual end date (Jan 2006) added as reported by ClinicalTrials.gov.